Talzenna (talazoparib)

Current FDA approved drugs and drugs in clinical trials targeted toward the genetic influences of breast cancer include those such as Talazoparib and Margetuximab. Additionally, risk assessment and genetic screening methods are incredibly important to inform patients of their individual risk for breast cancer development. Advancements in understanding of gene specific mechanism and their correlation with breast cancer pathogenesis may provide efficient strategies for precision medicine and enhancing clinical outcomes in breast cancer patients.

Among PARPi, Talazoparib (Talzenna®) is a potent therapy for patients with locally advanced or metastatic BC (mBC) with germline BRCA mutations (gBRCAm) and HER2-negative status, demonstrating the highest potency (IC50 = 0.57 nM), which is 4-10 times lower than that of other PARP inhibitors; olaparib (2.0 nM), rucaparib (1.9 nM), and veliparib (4.7 nM), indicating superior efficacy. The latest advancements in talazoparib research, including all related clinical trials (Phase 1-3) for the treatment of BC, OC, and other solid tumors (STs), are also summarized. A comprehensive analysis of all clinical trials involving talazoparib, whether as monotherapy or in combination with other drugs, elucidates its potential to improve clinical outcomes, address drug resistance, and explore synergistic combinations with other PARPi or novel agents, thereby providing insights into the clinical utility of talazoparib.

P1, N=35, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Sep 2025

P1/2, N=90, Recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Mar 2027

Drug sensitivity analysis identified potential therapeutic agents (CD-437 and talazoparib) targeting HNRNPA3-associated pathways. HNRNPA3 functions as a critical oncogenic regulator in BRCA by promoting tumor progression through cell cycle dysregulation and immune microenvironment remodeling. Its strong association with therapy resistance positions HNRNPA3 as both a prognostic biomarker and promising therapeutic target for breast cancer intervention strategies.

P1, N=45, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Sep 2026 --> Sep 2028

Docking/MD suggested a PARP-1 binding mode, with key interactions comparable to established inhibitors such as talazoparib and olaparib. In vitro genotoxicity assays showed that incubation of HCT-116 cell line with the compound 7 causes dose-dependent damage to DNA integrity. In vivo, compound 7 inhibited tumor growth in A549 xenografts (up to 75.1%, p < 0.05) and demonstrated dose-dependent activity in HCT-116 xenografts (up to 82.9% TGI at 6 mg/kg, i.v.).

P1/2, N=40, Active, not recruiting, Hospices Civils De Lyon | Recruiting --> Active, not recruiting

MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.

ASTX727 plus talazoparib produces significant myelosuppression without other adverse events. Modest methylation changes in PBMCs were detected. There were no objective responses, but some heavily pretreated patients had stable disease for >4 months despite the attenuated doses.

Her recent PNAS Inaugural Article identifies two escape routes in BRCA1-mutant tumors treated with talazoparib, pointing to new combination therapies. She emphasizes the value of mentorship and persistence in science.